SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma

Summary

The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into three parts: the safety run-in phase, randomized enrollment phase and cohort expansion phase.

Eligibility

Inclusion Criteria:

1. Age ≥18 years and ≤75 years
2. Histologically or cytologically confirmed unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC), who are ineligible for curative-intent therapies:

   * Safety run-in phase (Cohort 1, 2 and 3): received no more than 1 prior line of systemic therapy for locally advanced or metastatic ESCC.
   * Safety run-in phase (Cohort 4), randomized enrollment phase and cohort expansion phase: no prior systemic therapy for locally advanced or metastatic ESCC.
3. Participants are required to provide tumor tissue samples for biomarker analysis.
4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Life expectancy ≥ 12 weeks.

Exclusion Criteria:

1. Histology or cytology confirms the presence of concurrent adenocarcinoma components.
2. Leptomeningeal, brainstem, spinal, spinal cord compression, or active CNS metastases.
3. Risk of esophagotracheal/esophagopleural fistula, or symptomatic invasion/compression of vital organs/major blood vessels.
4. Active autoimmune disease requiring systemic therapy within past 2 years.
5. Weight loss ≥10% within 4 weeks prior to the first dose, or Nutritional Risk Index (NRI) \< 83.5.
6. Severe infection within 4 weeks or active infection requiring systemic treatment within 2 weeks pre-dose.
7. Uncontrolled comorbidities (e.g., decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, Grade ≥2 peripheral neuropathy).
8. Cardiovascular/cerebrovascular events within 6 months pre-dose (e.g., Myocardial Infarction, unstable angina, acute/persistent ischemia, Grade 3/4 Heart Failure, symptomatic/uncontrolled arrhythmia, Cerebrovascular Accident, Transient Ischemic Attack).
9. Uncontrolled hypertension, diabetes, or recurrent pleural/pericardial/abdominal effusion requiring drainage.
10. History of interstitial lung disease (ILD) or noninfectious pneumonitis that require steroid treatment, or currently has ILD/noninfectious pneumonitis.
11. Unresolved to grade ≤ 1 of prior anti-cancer treatment toxicities criteria per CTCAE v6.0.
12. Previously received B7-H3-targeted agents, including antibody, antibodydrug conjugate (ADC), and other agents.
13. Previously received treatment with an ADC that consists of a topoisomerase l inhibitor.
14. Pregnant or lactating women.

Conditions2

Interventions4

Related trials

• A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer — Multitude Therapeutics Inc.
• ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer — Hansoh BioMedical R&D Company
• Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer — Zhejiang Doer Biologics Co., Ltd.
• First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) — Qilu Hospital of Shandong University
• Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) — Fudan University
• Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV — Dai, Guanghai
• Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer — Hebei Medical University Fourth Hospital
• Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer — West China Hospital

Browse More Trials